Company profile: Alaunos Therapeutics
1.1 - Company Overview
Company description
- Provider of TCR-T cell therapies and supporting platforms for cancer treatment, including non-viral TCR-T therapy for solid tumors, the Sleeping Beauty transposition system for TCR gene transfer, the hunTR discovery engine to identify new TCRs, and a clinical TCR library targeting frequent mutations such as KRAS, TP53, and EGFR, backed by in-house manufacturing for rapid, cost-effective TCR-T production.
Products and services
- Clinical TCR Library: Mutation-targeted catalog that offers TCRs against frequent cancer mutations—KRAS, TP53, EGFR—for various cancers, enabling receptor selection aligned to prevalent mutation profiles
- Sleeping Beauty Transposition: Non-viral gene-transfer platform that introduces TCR genes into T cells, producing stable, long-term expression for cancer treatment through transposition
- TCR-T Cell Therapy: Non-viral, solid-tumor therapy that engineers patient T cells by modifying T‑cell receptors to recognize and attack cancer cells with precise, receptor-guided cytotoxicity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alaunos Therapeutics
Nuvalent
HQ: United States
Website
- Description: Provider of targeted therapies for clinically proven kinase targets in cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuvalent company profile →
Harpoon Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapy developing novel T cell-engaging biologic therapies that harness the body’s immune system to direct patients’ T cells to kill target cells in cancer and other diseases, including the TriTAC Technology antibody-based drug discovery platform designed to enhance immune targeting and killing of cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Harpoon Therapeutics company profile →
Tobira Therapeutics
HQ: United States
Website
- Description: Provider of research, discovery, acquisition, development, and commercialization of antiviral compounds for treating life-threatening and life-altering infectious diseases, including HIV/AIDS and hepatitis; develops TBR-652 and TBR-220 antagonists.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tobira Therapeutics company profile →
Anocca
HQ: Sweden
Website
- Description: Provider of biotechnology, immunology, and immunotherapeutic drug discovery and development services focused on T-cell biology, offering engineered TCR-T cell therapies and the Anocca OS platform for modeling, analysis, visualization, and automation, with a TCR-T oncology pipeline targeting diverse cancers and future programs for infectious diseases, autoimmunity, and allergies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anocca company profile →
BioVaxys
HQ: Canada
Website
- Description: Provider of immunotherapeutic cancer vaccines and delivery platforms. Haptenix uses haptens to train the immune system to recognize tumor or viral proteins; DPX is a lipid-based system for enhanced, sustained immune responses. Pipeline includes BVX-0918 (Phase I ovarian), Maveropepimut-S (DPX-formulated, Phase II for various cancers), and DPX SurMAGE (survivin/MAGE A9; bladder, lung, kidney; Phase I complete).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVaxys company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alaunos Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alaunos Therapeutics
2.2 - Growth funds investing in similar companies to Alaunos Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alaunos Therapeutics
4.2 - Public trading comparable groups for Alaunos Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →